Ainos, Inc. income statement
In fiscal 2025, Ainos, Inc. reported revenue of $124,157, up 499.0% on the year before, operating income of −$14.0m (a -11268.3% margin) and net income of −$14.8m, or −$3.46 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 0 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | — | — | — | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | — | — | — | 0 | 0 | 0 | 0 | 0 | 1 | −0 | −0 | 0 | 0 |
| Research and development | 0 | 0 | 0 | 0 | — | — | — | 0 | 0 | 0 | 2 | 7 | 7 | 8 | 8 | 8 |
| Selling, general and administrative | 1 | 1 | 0 | 0 | — | 1 | 1 | 1 | 2 | 1 | 2 | 9 | 6 | 5 | 6 | 6 |
| Operating income | −1 | −1 | −1 | −1 | — | −1 | −1 | −1 | −2 | −1 | −4 | −14 | −13 | −14 | −14 | −14 |
| Interest expense | 0 | 0 | 0 | 0 | — | 0 | 0 | 0 | — | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Income before tax | — | — | — | — | — | — | — | — | — | −0 | −0 | −14 | −14 | −15 | −15 | −14 |
| Income tax | — | — | — | — | — | 0 | — | — | 0 | 0 | — | 0 | 0 | 0 | 0 | — |
| Net income | 1 | −1 | −1 | −1 | — | −1 | −1 | −1 | −2 | −1 | −4 | −14 | −14 | −15 | −15 | −14 |
| Diluted EPS | $0.15 | −$0.30 | −$0.15 | −$0.15 | — | −$0.45 | −$0.45 | −$0.60 | −$0.60 | −$0.60 | −$0.45 | — | −$3.36 | −$7.82 | −$3.46 | −$2.49 |
| Diluted shares (average) | 4m | 4m | 5m | 5m | — | 1m | 2m | 2m | 3m | 3m | 8m | — | 4m | 2m | 4m | 6m |
| EBITDA | −1 | −1 | −1 | −1 | — | −1 | −1 | −1 | −2 | −1 | −2 | −9 | −8 | −9 | −9 | −9 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 106 | 5 | 2 | 11 | 0 | 0 |
| Cost of revenue | 1 | −0 | 18 | 1 | 0 | 2 | 1 | 0 |
| Gross profit | −1 | 0 | 88 | 4 | 2 | 10 | −1 | 0 |
| Research and development | 2,022 | 2,328 | 1,724 | 1,912 | 1,991 | 2,123 | 1,690 | 1,850 |
| Selling, general and administrative | 1,016 | 2,305 | 1,527 | 1,838 | 795 | 2,184 | 593 | 2,549 |
| Operating income | −3,039 | −4,634 | −3,163 | −3,746 | −2,784 | −4,298 | −2,284 | −4,399 |
| Interest expense | 265 | 184 | 180 | 178 | 177 | 177 | 177 | 200 |
| Income before tax | −3,699 | −4,653 | −3,286 | −4,085 | −2,932 | −4,467 | −2,460 | −4,595 |
| Net income | −3,699 | −4,654 | −3,286 | −4,085 | −2,932 | −4,468 | −2,460 | −4,595 |
| Diluted EPS | −$1.64 | −$1.33 | −$1.04 | −$0.99 | −$0.64 | −$0.85 | −$0.41 | −$0.62 |
| EBITDA | −1,827 | −3,442 | −1,986 | −2,552 | −1,578 | −3,096 | −1,110 | −3,213 |
Compare with peers
- Cuprina Holdings (cayman) LTD income statement
- Heartsciences Inc. income statement
- Phaos Technology Holdings (cayman) Ltd income statement
- Pavmed Inc. income statement
- Nexalin Technology, Inc. income statement
Head to head: AIMD vs CUPRAIMD vs HSCSAIMD vs POAS
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies